Last reviewed · How we verify
Ciprofloxacin DPI (BAYQ3939)
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Cystic fibrosis-associated Pseudomonas aeruginosa lung infection (inhaled formulation), Respiratory tract infections caused by susceptible gram-negative and gram-positive bacteria.
At a glance
| Generic name | Ciprofloxacin DPI (BAYQ3939) |
|---|---|
| Sponsor | Bayer |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase, Topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ciprofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This leads to accumulation of DNA breaks, cell death, and bactericidal activity. The DPI (dry powder inhaler) formulation is designed for direct pulmonary delivery to treat respiratory tract infections.
Approved indications
- Cystic fibrosis-associated Pseudomonas aeruginosa lung infection (inhaled formulation)
- Respiratory tract infections caused by susceptible gram-negative and gram-positive bacteria
Common side effects
- Cough
- Bronchospasm
- Dysgeusia (taste disturbance)
- Nausea
- Headache
Key clinical trials
- Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo (NA)
- Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (PHASE3)
- Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE) (PHASE3)
- Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin DPI (BAYQ3939) CI brief — competitive landscape report
- Ciprofloxacin DPI (BAYQ3939) updates RSS · CI watch RSS
- Bayer portfolio CI